Scaling highly potent API manufacturing for the next generation of therapies 

Highly potent active pharmaceutical ingredients (HPAPIs) are increasingly important in modern drug development, particularly for therapies such as oncology treatments that deliver clinical effects at very low doses. While these compounds offer significant therapeutic benefits, scaling HPAPI manufacturing from development to commercial production requires advanced containment strategies, robust process controls and specialist expertise. 

What is highly potent API (HPAPI) manufacturing? 

HPAPI manufacturing involves the development and production of pharmaceutical compounds that are effective at very low doses. 

Because these materials can present risks to operators if handled incorrectly, HPAPI facilities must be designed to protect both people and products while maintaining manufacturing efficiency and regulatory compliance. 

Why is containment critical in HPAPI manufacturing? 

Containment is one of the most important aspects of safe and successful HPAPI manufacturing because effective containment strategies help minimise operator exposure while protecting product quality and preventing cross-contamination. 

To achieve containment, manufacturers typically combine multiple layers of protection, including: 

• Closed processing systems
• Negative-pressure manufacturing environments
• Controlled airflow and filtration systems
• Strict personal protective equipment (PPE) procedures
• Environmental monitoring programmes 

As regulatory expectations continue to evolve, manufacturers must also demonstrate that containment measures remain effective throughout the production process through risk management, monitoring and cleaning validation activities. 

What challenges arise when scaling HPAPI production? 

Scaling HPAPI manufacturing from laboratory and development environments to commercial production introduces additional complexity. 

Larger batch sizes can create new challenges, including: 

• Increased dust generation
• Changes in material behaviour
• Greater demands on airflow and filtration systems
• More complex cleaning requirements
• Increased equipment size and operational considerations 

Successfully managing these challenges requires careful planning and a manufacturing strategy that supports both containment and operational consistency. 

How can manufacturers ensure successful process transfer and scale-up? 

Maintaining reproducibility across manufacturing sites is essential when transferring HPAPI processes from development to commercial production. 

Successful scale-up programmes typically consider: 

• Containment requirements
• Equipment configuration
• Process consistency
• Cleaning validation approaches
• Site-to-site operational alignment 

A well-planned process transfer strategy helps ensure that product quality, safety and performance are maintained throughout the transition. 

How are new technologies improving HPAPI manufacturing? 

Many contract development and manufacturing organisations (CDMOs) are adopting advanced technologies to improve process control and support safe scale-up. 

These technologies may include: 

• Predictive modelling tools
• Real-time monitoring systems
• Manufacturing automation
• Enhanced data collection and analysis 

By increasing process visibility and reducing manual intervention, these solutions can help improve manufacturing efficiency while reducing operator exposure. 

What should pharmaceutical companies look for in an HPAPI manufacturing partner? 

As demand for highly potent therapies continues to grow, pharmaceutical companies are increasingly seeking CDMO partners with: 

• Proven containment expertise
• Scalable manufacturing capabilities
• Strong regulatory knowledge
• Experience transferring processes from development to commercial production
• Advanced process monitoring and control capabilities 

Selecting the right manufacturing partner can help ensure a successful path from development to commercial supply. 

Want to learn the essentials of scaling HPAPI manufacturing? 

Lidia Garcia Martin, MSAT & New Productions Head at Recipharm, outlines the key operational and regulatory considerations shaping modern HPAPI manufacturing and explains how CDMOs can prepare for the next generation of highly potent therapies.
Read the full article in Pharmaceutical Outsourcing.